NCT04051112View on ClinicalTrials.gov

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 28, 2019

Primary Completion Date

December 24, 2021

Study Completion Date

April 21, 2022

Conditions

Malignant Ascites

Interventions

DRUG

SCB-313

10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle

Trial Locations (1)

200126

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Sichuan Clover Biopharmaceuticals, Inc.

INDUSTRY

NCT04051112 - Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites | Biotech Hunter | Biotech Hunter